David Ting is an Oncology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Mgh - Yawkey 7b
Boston, MA 021142621
Telephone
617-724-4000Registry record last updated 8 Oct 2013.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- LEICA MICROSYSTEMS INC.Program year20241 payment
- ModernaTX, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
60%SSRI40%Fluvoxamine Maleate50%Escitalopram Oxalate50%Part D<11 patientsAzaspirodecanedione derivatives20%Buspirone Hcl100%Part D<11 patientsCardiovascular
20%ACE inhibitor20%Lisinopril100%Part D<11 patientsMetabolism & gastrointestinal
20%H2 blocker20%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2023 per NIH RePORTER. The latest:
- Reverse transcriptase inhibitor effects on the mobilome of colon cancer
Massachusetts General Hospital
FY2023$565,924R01CA240924 - Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
Massachusetts General Hospital
FY2023$562,581R01CA235412 - Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
Massachusetts General Hospital
FY2023$233,789R01CA235412
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”